Page 4 - Patrick Forde News Today

Immune-boosting drug may help before lung cancer surgery MARILYNN MARCHIONE, AP Chief Medical Writer April 12, 2021 FacebookTwitterEmail FILE - This product image provided by Bristol-Myers Squibb shows their drug Opdivo. On Saturday, April 10, 2021, doctors say that the drug, which helps the immune system fight cancer, gave dramatic results when used with chemotherapy before surgery in patients with operable lung tumors. (Bristol-Myers Squibb via AP)AP A drug that helps the immune system fight...

Marilynn Marchione FILE - This product image provided by Bristol-Myers Squibb shows their drug Opdivo. On Saturday, April 10, 2021, doctors say that the drug, which helps the immune system fight cancer, gave dramatic results when used with chemotherapy before surgery in patients with operable lung tumors. (Bristol-Myers Squibb via AP) April 12, 2021 - 9:55 AM A drug that helps the immune system fight cancer gave dramatic results when used with chemotherapy before sur...

Share it The American Association of Cancer Researchs virtual meeting, one of the years biggest conferences in oncology, was in full swing over the weekend and will continue over the next few days. Though the gathering typically focuses on early research and clinical work — rather than the larger trials that change medical practice — there has been a bit of both at this years meeting. Key updates included fresh data on a new immunotherapy target, encouraging results for a new type of cell t...

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy. DREAM3R will determine if concurrent chemo-...

 E-Mail IMAGE: Patrick Forde, MD, is the lead US investigator for the newly opened DREAM3R clinical trial, which is evaluating chemo-immunotherapy in patients with malignant pleural mesothelioma. view more  Credit: Johns Hopkins University The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in inde...

 E-Mail The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival. In fact, patients who developed two irAEs did better, in terms of delaying the time to cancer progression and overall survival, than those who developed only one...